parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.01 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in choroid plexus epithelial cells	0.75
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 416	0.91
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 8786

receipt 8794: TRPM3 in dopamine neurons, braak

power: full sample +0.19 (p 0.460, n 18), 95% CI -0.31 to +0.60. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.14 (p 0.567, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.07 (p 0.794, n 18). could be the mix.
skeptic: leave-one-out range +0.12 to +0.36, sign flips 0; without severely affected donors +0.19 (p 0.460, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for TRPM3 in dopamine neurons.

case closed: nothing better to follow up.

receipt 8793: TRPM3 in astrocytes, braak

power: full sample +0.26 (p 0.289, n 18), 95% CI -0.23 to +0.65. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.28 (p 0.265, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.46 (p 0.052, n 18). could be the mix.
skeptic: leave-one-out range +0.17 to +0.37, sign flips 0; without severely affected donors +0.26 (p 0.289, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for TRPM3 in astrocytes.

case closed: nothing better to follow up.

loading the receipts